{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:37:01Z","timestamp":1795124221333,"version":"4.10.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To characterize the effect of upadacitinib 15\u2009mg once daily (UPA15) on enthesitis in patients with PsA from the SELECT-PsA Phase 3 trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with an inadequate response\/intolerance to one or more non-biologic DMARD (SELECT-PsA 1) or one or more biologic DMARD (SELECT-PsA 2) received UPA15, adalimumab 40\u2009mg every other week or placebo (weeks 0\u201324) switched to UPA15 (week 24 onward). The Leeds Enthesitis Index (LEI) and Spondyloarthritis Research Consortium of Canada (SPARCC) index were used to assess improvement in enthesitis, enthesitis resolution, maintenance of enthesitis resolution and protection from enthesitis development through week 56.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 639 patients receiving UPA15 and 635 patients receiving placebo (including 317 patients who switched from placebo to UPA15) were analysed. UPA15 led to higher rates of enthesitis resolution vs placebo at week 24 (LEI: 59.8% vs 38.0%; SPARCC index: 50.6% vs 31.5%, respectively) and greater improvements in the LEI (\u20131.7 vs \u20131.0) and SPARCC index (\u20133.4 vs \u20131.9); improvements were maintained through week 56. Improvements were observed after 12\u2009weeks of UPA15 treatment. Over 90% of patients without enthesitis (LEI\u2009=\u20090) at baseline receiving UPA15 were enthesitis-free at week 56, and UPA15 prevented recurrence of enthesitis at week 56 in &amp;gt;80% of patients with enthesitis at baseline who achieved resolution (LEI\u2009=\u20090) at week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>UPA15 is associated with a comprehensive improvement in enthesitis, with improvements observed after 12\u2009weeks of treatment. Additionally, treatment with UPA15 was associated with maintaining an enthesitis-free state after resolution and protection against new-onset enthesitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov identifiers: NCT03104400 (SELECT-PsA 1) and NCT03104374 (SELECT-PsA 2).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae057","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:39:35Z","timestamp":1707439175000},"page":"3146-3154","source":"Crossref","is-referenced-by-count":8,"title":["Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a <i>post hoc<\/i> analysis of SELECT-PsA 1 and 2 trials"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-043X","authenticated-orcid":false,"given":"Fabrizio","family":"Cantini","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato , Prato,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Humanitas San Pio X , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-0909","authenticated-orcid":false,"given":"Lucia","family":"Novelli","sequence":"additional","affiliation":[{"name":"Medical Department, AbbVie srl , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Gualberti","sequence":"additional","affiliation":[{"name":"Medical Department, AbbVie srl , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-3112","authenticated-orcid":false,"given":"Francesca","family":"Marando","sequence":"additional","affiliation":[{"name":"Medical Department, AbbVie srl , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L","family":"McDearmon-Blondell","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds,","place":["UK"]},{"name":"Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia , Reggio Emilia,","place":["Italy"]},{"name":"Universit\u00e0 di Modena e Reggio Emilia , Reggio Emilia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"2024110419222925100_keae057-B1","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024110419222925100_keae057-B2","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419222925100_keae057-B3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.191117","article-title":"Disease characteristics, quality of life, and work productivity by enthesitis site: real-world data from the US Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"48","author":"Mease","year":"2021","journal-title":"J Rheumatol"},{"key":"2024110419222925100_keae057-B4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024110419222925100_keae057-B5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024110419222925100_keae057-B6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11926-018-0751-3","article-title":"Enthesitis: much more than focal insertion point inflammation","volume":"20","author":"Watad","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2024110419222925100_keae057-B7","author":"Rinvoq","year":"2022"},{"key":"2024110419222925100_keae057-B8","author":"Rinvoq","year":"2022"},{"key":"2024110419222925100_keae057-B9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"2024110419222925100_keae057-B10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024110419222925100_keae057-B11","first-page":"275","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the Phase 3 SELECT-PsA 1 study","volume":"10","author":"McInnes","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024110419222925100_keae057-B12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2022-eular.1897","article-title":"Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis refractory to biologic therapies: 2-year results from the Phase 3 SELECT-PsA 2 study","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024110419222925100_keae057-B13","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1093\/rheumatology\/keaa042","article-title":"Enthesitis in psoriatic arthritis (part 3): clinical assessment and management","volume":"59","author":"Mease","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419222925100_keae057-B14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/annrheumdis-2016-209454","article-title":"A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis","volume":"76","author":"De Wilde","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024110419222925100_keae057-B15","first-page":"418","article-title":"Upadacitinib effectively limits IL-23 driven inflammation at the enthesis by inhibiting T cell STAT1 phosphorylation, IL-17A and TNF\u03b1 production","volume":"81(Suppl 1)","author":"Giryes","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024110419222925100_keae057-B16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2024110419222925100_keae057-B17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2021-eular.884","article-title":"The effect of filgotinib on enthesitis: 100-week data from an open-label extension study in patients with active psoriatic arthritis","volume":"80","author":"Helliwell","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024110419222925100_keae057-B18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2024110419222925100_keae057-B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2024110419222925100_keae057-B20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","article-title":"A novel treatment for psoriatic arthritis: janus kinase inhibitors","volume":"133","author":"Chen","year":"2020","journal-title":"Chin Med J (Engl)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae057\/56660014\/keae057.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/3146\/60415556\/keae057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/3146\/60415556\/keae057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T19:22:48Z","timestamp":1730748168000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/11\/3146\/7603979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,2,8]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae057","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,2,8]]}}}